Skip to main content

Table 2 Subject characteristics

From: Investigating the role of neuropathic pain relief in decreasing gait variability in diabetes mellitus patients with neuropathic pain: a randomized, double-blind crossover trial

 

All study subjects (n = 28)

Subjects completing study (n = 19)

Age

64.6 ± 10.4 years

65.7 ± 10.8 years

Gender (males)

17/28 (61%)

16/19 (84%)

Duration of Diabetes Mellitus

7.2 ± 3.9 years

7.5 ± 4.1 years

Duration of Neuropathic Symptoms

5.7 ± 4.1 years

6.0 ± 4.3 years

Concomitant Diabetic

  

Complications Present (other than neuropathy)

5/28 (18%)

3/19 (16%)

Other Neuropathic Pain Medications Used

1.2 ± 1.1

1.4 ± 1.2

Weight (kg)

96.3 ± 26.8

94.6 ± 25.9

Height (cm)

170.9 ± 7.6

169.7 ± 7.8

Sitting Systolic Blood Pressure (mm Hg)

141 ± 18

139 ± 18

Sitting Heart Rate (/min)

72 ± 10

74 ± 12

Standing Systolic Blood Pressure (mm Hg)

140 ± 19

136 ± 20

Standing Heart Rate (/min)

73 ± 12

73 ± 13

Utah Early Neuropathy

16.3 ± 9.6

16.2 ± 6.5

Score

  

Douleur Neuropathique 4 Score

7.6 ± 1.0

6.9 ± 0.9

  

Block 1 Pregabalin Intervention

Block 1 Placebo Intervention

Baseline Visual Analog Pain Score

 

6.1 ± 1.6

7.1 ± 1.3

Average Pregabalin

 

205.8 ± 28.9

188.1 ± 39.8

Dosage Achieved (mg)

   

Other Neuropathic Pain Medications Used

 

1.4 ± 1.2

1.4 ± 1.2

  1. Values shown are means ± standard deviations.